UK Must Use Biosimilar Savings To Provide Earlier Access To Biologics
Executive Summary
The UK may be busy sweeping up the savings being generated with the rapid uptake of biosimilars, but more needs to be done to show how this money is being channelled back into the healthcare system to the benefit of patients.
You may also be interested in...
Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars
Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.